This HTML5 document contains 71 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n24http://linked.opendata.cz/resource/AHFS/
n4http://linked.opendata.cz/resource/drugbank/company/
n16http://linked.opendata.cz/resource/drugbank/dosage/
n15http://linked.opendata.cz/resource/drugbank/mixture/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00803/identifier/chemspider/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/drug/DB00803/identifier/wikipedia/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00803/identifier/pharmgkb/
n22http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00803/identifier/kegg-compound/
n11http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00803/identifier/pubchem-compound/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00803/identifier/kegg-drug/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00803/identifier/pubchem-substance/
n13http://linked.opendata.cz/resource/atc/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00803/identifier/drugbank/
n12http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00803
rdf:type
n3:Drug
n3:description
Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally. [PubChem]
n3:dosage
n16:271B3F12-363D-11E5-9242-09173F13E4C5 n16:271B3F13-363D-11E5-9242-09173F13E4C5 n16:271B3F14-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
5 hours
n3:indication
For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly <i>Pseudomonas aeruginosa</i>.
n3:manufacturer
n4:271B3F0F-363D-11E5-9242-09173F13E4C5
owl:sameAs
n7:DB00803 n22:DB00803
dcterms:title
Colistin
adms:identifier
n9:PA164760862 n10:Colistin n17:DB00803 n18:C13768 n19:4470591 n20:5311054 n21:46505467 n23:D02138
n3:mechanismOfAction
Colistin is a surface active agent which penetrates into and disrupts the bacterial cell membrane. Colistin is polycationic and has both hydrophobic and lipophilic moieties. It interacts with the bacterial cytoplasmic membrane, changing its permeability. This effect is bactericidal. There is also evidence that polymyxins enter the cell and precipitate cytoplasmic components, primarily ribosomes.
n3:packager
n4:271B3F0E-363D-11E5-9242-09173F13E4C5
n3:synonym
Colistin Colistina Colistine Colistinum Polymyxin E
n3:toxicity
Oral LD<sub>50</sub> in rats is 5450 mg/kg. Overdosage with colistimethate can cause neuromuscular blockade characterized by paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, disorders of speech and apnea. Respiratory muscle paralysis may lead to apnea, respiratory arrest and death.
n12:hasAHFSCode
n24:08-12-28-28
n3:mixture
n15:271B3F0A-363D-11E5-9242-09173F13E4C5 n15:271B3F0D-363D-11E5-9242-09173F13E4C5 n15:271B3F0B-363D-11E5-9242-09173F13E4C5 n15:271B3F0C-363D-11E5-9242-09173F13E4C5
n3:salt
n3:IUPAC-Name
n5:271B3F19-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B3F1F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B3F1E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B3F1B-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B3F1C-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B3F1D-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B3F17-363D-11E5-9242-09173F13E4C5 n5:271B3F2F-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B3F31-363D-11E5-9242-09173F13E4C5 n5:271B3F18-363D-11E5-9242-09173F13E4C5 n5:271B3F15-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B3F16-363D-11E5-9242-09173F13E4C5
n12:hasATCCode
n13:A07AA10 n13:J01XB01
n3:H-Bond-Acceptor-Count
n5:271B3F25-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B3F26-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B3F20-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B3F21-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B3F23-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B3F22-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B3F24-363D-11E5-9242-09173F13E4C5
n3:absorption
Very poor absorption from gastrointestinal tract.
n3:affectedOrganism
Gram-negative bacilli
n3:casRegistryNumber
1264-72-8
n3:category
n3:containedIn
n11:271B3F10-363D-11E5-9242-09173F13E4C5 n11:271B3F11-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B3F2B-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B3F2D-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B3F2E-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B3F30-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B3F2A-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B3F29-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B3F2C-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B3F1A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B3F27-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B3F28-363D-11E5-9242-09173F13E4C5